Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Pre-Mkt 11-06 07:07:24 EST

0.6204

-0.0176

-2.76%

盘前0.7000

+0.0796+12.83%

04:00 EST

High0.6599	Low0.5671	Vol766.17K
Open0.6550	D1 Closing0.6380	Amplitude14.55%
Mkt Cap79.43M	Tradable Cap39.60M	Total Shares128.03M
T/O472.87K	T/O Rate1.20%	Tradable Shares63.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":0.6204,"timestamp":1793912400000,"preClose":0.638,"halted":0,"volume":766174,"hourTrading":{"tag":"盘前","latestPrice":0.7,"preClose":0.6204,"latestTime":"04:00 EST","volume":1,"amount":0.7,"timestamp":1793955620287,"change":0.0796,"changeRate":0.128304,"amplitude":0},"delay":0,"changeRate":-0.027586206896551817,"floatShares":63832528,"shares":128028624,"eps":-0.20328,"marketStatus":"Pre-Mkt","change":-0.0176,"latestTime":"11-06 07:07:24 EST","open":0.655,"high":0.6599,"low":0.5671,"amount":472871,"amplitude":0.145455,"askPrice":0.7381,"askSize":100,"bidPrice":0.63,"bidSize":1784,"shortable":0,"etf":0,"ttmEps":-0.20328,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793975400000},"marketStatusCode":1,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":0.6204,"preHourTrading":{"tag":"盘前","latestPrice":0.7,"preClose":0.6204,"latestTime":"04:00 EST","volume":1,"amount":0.7,"timestamp":1793955620287,"change":0.0796,"changeRate":0.128304,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.6204,"preClose":0.6204,"latestTime":"16:22 EST","volume":3,"amount":1.8641,"timestamp":1793913752671,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7237562391863406,"impliedVol":1.1411,"impliedVolPercentile":0.956},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2681006270","title":"Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2681006270","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681006270?lang=en_us&edition=fundamental","pubTime":"2026-11-06 03:00","pubTimestamp":1793905242,"startTime":"0","endTime":"0","summary":"Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis TrialTiziana Life Sciences will discuss previously announced Phase 2a INFORM-MS results for intranasal foralumab at an invest","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL6NThMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680713845","title":"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Tiziana Life Sciences (TLSA) and Verastem (VSTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680713845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680713845?lang=en_us&edition=fundamental","pubTime":"2026-11-03 10:41","pubTimestamp":1793673683,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY), Tiziana Life Sciences (TLSA) and Vera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-tiziana-life-sciences-tlsa-and-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-tiziana-life-sciences-tlsa-and-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0096364046.USD","LU1032466523.USD","LU0058720904.USD","LU0128526141.USD","LU1868837300.USD","LU0029874061.USD","LU2125154935.USD","VSTM","BK4137","TLSA","HCSG","LU0985481810.HKD","LU1261432733.SGD","LU1868837136.USD","LU0225771236.USD","XBI","LU0237698245.USD","LU1670711123.USD","LU2125154778.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU0321505439.SGD","IE00BFXG1179.USD","FTXH","LABU","LU0882574055.USD","LU1868836914.USD","IE0002141913.USD","BMY","LU0306806265.USD","LU2360032135.SGD","LU0061475181.USD","LU0289739699.SGD","LU1989771016.USD","LU1670710661.SGD","BK4585","LU0267386448.USD","LU1883839398.USD","LU1983299246.USD","LU1670711040.USD","BK4139","LU0306807586.USD","IHE","LU1236620834.HKD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU0432979614.USD","XLV","LU1868836591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680953763","title":"Tiziana Life Sciences Clarifies October Filing is Incorporated into Registration Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2680953763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680953763?lang=en_us&edition=fundamental","pubTime":"2026-11-02 22:15","pubTimestamp":1793628928,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Clarifies October Filing Is Incorporated Into Registration StatementsTiziana Life Sciences amended its October 16, 2026, Form 6-K on November 2, 2026, solely to incorporate it into registration statements.The incorporation applies to Form F-3  and Form S-8 .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL5QHtmM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680752144","title":"Tiziana's Experimental MS Treatment Meets Main Goals in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2680752144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680752144?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:42","pubTimestamp":1793623345,"startTime":"0","endTime":"0","summary":"Tiziana's experimental MS treatment meets main goals in mid-stage studyNov 2 -Tiziana Life SciencesTLSA.Osaid on Monday its experimental therapy for a progressive form of multiple sclerosis with no approved treatments reduced brain inflammation and showed a favorable safety profile in a mid-stage trial.Shares of the biopharmaceutical company were up more than 7% in premarket trading.The study met both primary endpoints, with the 50-microgram dose of the nasal treatment significantly reducing brain inflammation versus placebo, while both the 50- and 100-microgram doses met safety goals, Tiziana saidPatients receiving the treatment foralumab showed clinically meaningful reductions in fatigue after 12 weeks, while the placebo group did not, according to the companyMultiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord; Tiziana said its non-active secondary progressive form involves gradually worsening disability without flare-ups or new signs of disease activ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL3N46J0XA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751044","title":"Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751044?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:05","pubTimestamp":1793621100,"startTime":"0","endTime":"0","summary":"Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis TrialTiziana Life Sciences announced its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL74JJM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751972","title":"Tiziana Announces Positive Topline Results from Phase 2a Inform-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751972?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:00","pubTimestamp":1793620802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA4L0VKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751171","title":"Tiziana Life Sciences - All 48 Participants Completed Treatment with no Deaths or Study-Drug Related Saes","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751171?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:00","pubTimestamp":1793620802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA4L0VKC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751126","title":"Tiziana Life Sciences - Inform-MS Trial Meets Dual Primary Endpoints for Microglial Activation and Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751126?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:00","pubTimestamp":1793620802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA4L0VKC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519777","title":"Tiziana Life Sciences - Both 50 Ug and 100 Ug Doses of Foralumab Safe and Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680519777?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:00","pubTimestamp":1793620802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA4L0VKC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677622605","title":"TLSA’s BANYAN Trial: Nasal ALS Therapy Enters the Spotlight for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2677622605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677622605?lang=en_us&edition=fundamental","pubTime":"2026-10-22 00:30","pubTimestamp":1792600240,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (US) ($TLSA) announced an update on their ongoing clinical study. The BANYAN Trial is a Phase 2a study testing a nasal spray ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tlsas-banyan-trial-nasal-als-therapy-enters-the-spotlight-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tlsas-banyan-trial-nasal-als-therapy-enters-the-spotlight-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLSA","BK4211","ISBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677673314","title":"Tiziana Life Sciences Attends 10th Joint Actrims-Ectrims Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2677673314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677673314?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:02","pubTimestamp":1792580526,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Attends 10th Joint ACTRIMS-ECTRIMS MeetingTiziana Life Sciences management will attend the 10th joint ACTRIMS-ECTRIMS meeting in Toronto, Oct. 21-23, 2026.Representatives will di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL6gjTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","BK4112","TLSA","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","NDAQ","IE00BQXX3F31.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676682795","title":"Musk Adds Neuralink CEO Back on His Resume","url":"https://stock-news.laohu8.com/highlight/detail?id=2676682795","media":"Dow Jones","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676682795?lang=en_us&edition=fundamental","pubTime":"2026-10-19 23:30","pubTimestamp":1792423800,"startTime":"0","endTime":"0","summary":"Already the chief of SpaceX and Tesla, Elon Musk has publicly added his name as CEO of another-Neuralink.In a new Tesla securities filing, his biography was updated to include Neuralink in the list of companies where he is CEO. He's still listed as just a founder of The Boring Company, another of his side projects.Musk has called himself CEO of Neuralink before, and he was widely assumed to be overseeing the company, but Neuralink disclosed little about its governance since the brain computer interface company started in 2016.The company in August filed paperwork in Nevada listing its directors, which include Neuralink co-founder DJ Seo as president of the company; Jared Birchall, the head of Musk's family office; Musk ally and SpaceX board member Antonio Gracias; Joe Lonsdale from 8VC; and Scott Nolan from Founders Fund.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675592486","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2675592486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675592486?lang=en_us&edition=fundamental","pubTime":"2026-10-16 20:57","pubTimestamp":1792155426,"startTime":"0","endTime":"0","summary":"Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sector SPDR ETF  up 0.4% and the iShares Biotechnology ETF  advancing by 0.5%.Tiziana Life Sciences  stock was up more than 1% after the company said it has started dosing the last patient in the phase 2 trial of intranasal foralumab in patients with early/mild Alzheimer's disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","TLSA","XBI","BK4585","HCSG","BK4588","IBB","LABU","BK4139","LU0029874061.USD","BK4581","XLV","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559978","title":"Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559978","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675559978?lang=en_us&edition=fundamental","pubTime":"2026-10-16 19:25","pubTimestamp":1792149905,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  said Friday it has started dosing the last patient under the phase 2 trial of intranasal foralumab in patients with early/mild Alzheimer's disease.The trial is evaluating intranasal foralumab both as monotherapy and in combination with lecanemab or donanemab, with key endpoints such as changes in neuroinflammation, cognitive function and fluid biomarkers, the company said.Tiziana said it expects to release the trial's topline data in Q1 2027.Shares of the company rose more than 1% in recent premarket activity Friday.Price: 1.07, Change: +0.02, Percent Change: +1.90","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675962095","title":"Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2675962095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675962095?lang=en_us&edition=fundamental","pubTime":"2026-10-16 19:00","pubTimestamp":1792148400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUA5GNCWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675723596","title":"Tiziana Life Sciences Ltd: Topline Data are Anticipated to be Announced in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2675723596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675723596?lang=en_us&edition=fundamental","pubTime":"2026-10-16 19:00","pubTimestamp":1792148400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUA5GNCWS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673700002","title":"Tiziana Life Sciences (TLSA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673700002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673700002?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:35","pubTimestamp":1791207349,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Tiziana Life Sciences, with a price target of $7.00. According to T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tiziana-life-sciences-tlsa-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tiziana-life-sciences-tlsa-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671050012","title":"Tiziana Life Sciences - Submits Request to FDA for Orphan Drug Designation for Intranasal Foralumab for Msa","url":"https://stock-news.laohu8.com/highlight/detail?id=2671050012","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671050012?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766054,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For MsaSept 30 (Reuters)-Tiziana Life Sciences LtdTLSA.O:TIZIANA LIFE SCIENCES - SUBMITS REQUE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M0VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670231179","title":"Tiziana Life announces first 3 participants received first dose in ALS BANYAN","url":"https://stock-news.laohu8.com/highlight/detail?id=2670231179","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670231179?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:10","pubTimestamp":1790593841,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced that the first three participants have all received their first dose of intranasal foralumab in the Phase 2a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-first-3-participants-received-first-dose-in-als-banyan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-first-3-participants-received-first-dose-in-als-banyan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670392752","title":"Tiziana Life Sciences Doses First Patients in Phase 2a Intranasal Foralumab ALS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670392752","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670392752?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593223,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences doses first patients in Phase 2a intranasal foralumab ALS trialTiziana Life Sciences dosed the first three participants in a Phase 2a trial of intranasal foralumab in ALS.No resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL46l6Gl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","IE00BQXX3F31.USD","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","SG9999014005.SGD","TLSA","BK4588","BK4585","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BK4139","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00BN0W2V16.EUR","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":-0.3142},{"period":"1month","weight":-0.4411},{"period":"3month","weight":-0.3796},{"period":"6month","weight":-0.6073},{"period":"1year","weight":-0.6628},{"period":"ytd","weight":-0.5836}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.062066},{"month":2,"riseRate":0.125,"avgChangeRate":0.000048},{"month":3,"riseRate":0.375,"avgChangeRate":0.130911},{"month":4,"riseRate":0.625,"avgChangeRate":0.144279},{"month":5,"riseRate":0.5,"avgChangeRate":0.187138},{"month":6,"riseRate":0.375,"avgChangeRate":-0.011823},{"month":7,"riseRate":0.375,"avgChangeRate":0.26158},{"month":8,"riseRate":0.25,"avgChangeRate":-0.130353},{"month":9,"riseRate":0.375,"avgChangeRate":0.001357},{"month":10,"riseRate":0.25,"avgChangeRate":-0.102185},{"month":11,"riseRate":0,"avgChangeRate":-0.139842},{"month":12,"riseRate":0,"avgChangeRate":-0.132657}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}